These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 28902794

  • 1. Lymph Node Metastasis in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors.
    Martin JA, Warner RRP, Aronson A, Wisnivesky JP, Kim MK.
    Pancreas; 2017 Oct; 46(9):1214-1218. PubMed ID: 28902794
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors.
    Kim MK, Warner RR, Ward SC, Harpaz N, Roayaie S, Schwartz ME, Itzkowitz S, Wisnivesky J.
    Neuroendocrinology; 2015 Oct; 101(1):58-65. PubMed ID: 25572143
    [Abstract] [Full Text] [Related]

  • 3. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS, Chen M, Kim JH, Kim WH, Ahn S, Maeng K, Allegra CJ, Kaye FJ, Hochwald SN, Zajac-Kaye M.
    Int J Cancer; 2014 Jul 01; 135(1):128-37. PubMed ID: 24347111
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M, Čačev T, Catela Ivković T, Marout J, Ulamec M, Zjačić-Rotkvić V, Kapitanović S.
    Mol Cell Endocrinol; 2016 Apr 15; 425():61-8. PubMed ID: 26805636
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Tumors.
    Fitzgerald TL, Mosquera C, Lea CS, McMullen M.
    Am Surg; 2017 Jul 01; 83(7):799-803. PubMed ID: 28738955
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y, Wang YF, Tan BB, Er LM, Zhao Q, Fan LQ, Zhang ZD, Liu Y.
    Zhonghua Zhong Liu Za Zhi; 2020 May 23; 42(5):426-431. PubMed ID: 32482035
    [Abstract] [Full Text] [Related]

  • 13. Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?
    DePalo DK, Lee RM, Lopez-Aguiar AG, Gamboa AC, Rocha F, Poultsides G, Dillhoff M, Fields RC, Idrees K, Nathan H, Abbott D, Maithel SK, Russell MC, other members of the United States Neuroendocrine Tumor Study Group.
    J Surg Oncol; 2019 Nov 23; 120(6):919-925. PubMed ID: 31385621
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Validated Risk-Score Model Predicting Lymph Node Metastases in Patients with Non-Functional Gastroenteropancreatic Neuroendocrine Tumors.
    Shannon AB, Straker RJ, Fraker DL, Miura JT, Karakousis GC.
    J Am Coll Surg; 2022 May 01; 234(5):900-909. PubMed ID: 35426404
    [Abstract] [Full Text] [Related]

  • 19. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
    Watanabe A, Yip L, Hamilton TD, Loree JM, Stuart HC.
    Am J Surg; 2021 Jun 01; 221(6):1141-1149. PubMed ID: 33795127
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.